JD Health International (FRA:8ZN) EBIT: €731 Mil (TTM As of Dec. 2025)


FRA:8ZN JD Health International Inc FRA:8ZN
90 GF Score
Price €3.72
GF Value €6.38
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is JD Health International EBIT?

JD Health International FRA:8ZN +1.61% 90 EBIT is €731 Mil as of Dec. 2025. GuruFocus rates FRA:8ZN with a GF Score™ of 90/100 and a GF Value™ of €6.38 (Significantly Undervalued). The stock has 1 warning sign investors should review.

JD Health International's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €385 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €731 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JD Health International's annualized ROC % for the quarter that ended in Dec. 2025 was 12.14%. JD Health International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 579.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. JD Health International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.61%.

JD Health International  (FRA:8ZN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JD Health International's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=426.382 * ( 1 - 12.34% )/( (2752.326 + 3407.15)/ 2 )
=373.7664612/3079.738
=12.14 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9473.696 - 2094.619 - ( 5953.454 - max(0, 2404.03 - 7030.781+5953.454))
=2752.326

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9892.514 - 2167.915 - ( 5838.33 - max(0, 2514.931 - 6832.38+5838.33))
=3407.15

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

JD Health International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=769.526/( ( (116.403 + max(-1312.564, 0)) + (149.198 + max(-1496.847, 0)) )/ 2 )
=769.526/( ( 116.403 + 149.198 )/ 2 )
=769.526/132.8005
=579.46 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.224 + 900.184 + 125.446) - (2094.619 + 0 + 290.799)
=-1312.564

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(52.171 + 831.57 + 109.287) - (2167.915 + 0 + 321.96)
=-1496.847

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

JD Health International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=731.041/5799.187
=12.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JD Health International EBIT Related Terms

JD Health International EBIT Historical Data

* Premium members only.

The historical data trend for JD Health International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JD Health International EBIT Chart

JD Health International Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -124.43 95.45 347.12 630.25 732.49

JD Health International Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.38 312.89 309.76 346.28 384.76

JD Health International EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, JD Health International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JD Health International EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, JD Health International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JD Health International's EV-to-EBIT falls into.


FRA:8ZN
90GF Score
JD Health International Inc FRA:8ZN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JD Health International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €731 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €731 Mil mean?
JD Health International (FRA:8ZN) has a EBIT of €731 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on JD Health International.
Is JD Health International's EBIT too high?
JD Health International's current EBIT is €731 Mil. Overall, JD Health International has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JD Health International's EBIT compare to competitors?
JD Health International's EBIT of €731 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on JD Health International. JD Health International's current EBIT is €731 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JD Health International stock overvalued right now?
Based on GuruFocus' analysis, JD Health International (FRA:8ZN) is currently considered Significantly Undervalued. The stock's GF Value™ is €6.38, compared to a current price of €3.72 — trading 41.7% below its estimated fair value. The current EBIT is €731 Mil. JD Health International's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For JD Health International (FRA:8ZN), the current EBIT is €731 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JD Health International (FRA:8ZN) Overvalued in 2026?

Based on GuruFocus' analysis, JD Health International stock appears to be undervalued. The current stock price of €3.72 is trading 41.7% below its estimated GF Value™ of €6.38. GuruFocus considers JD Health International to be Significantly Undervalued.

Key valuation signals for FRA:8ZN:

  • EBIT: €731 Mil
  • GF Value™: €6.38 vs. price of €3.72 (41.7% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the FRA:8ZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JD Health International Business Description

Address No. 20 Kechuang 11 Street, Block C, Building 2, Jingdong Headquarters, Economic and Technological Development Zone, Daxing District, Beijing, CHN, 101111
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
90GF Score

Get the complete analysis for FRA:8ZN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.72
Price
€6.38
GF Value